• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?

作者信息

Kartolo Adi, Robinson Andrew, Fung Andrea S

机构信息

Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, K7L 3N6, Canada.

出版信息

Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12.

DOI:10.2217/fon-2021-1348
PMID:35018801
Abstract
摘要

相似文献

1
Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?肺癌的最佳一线免疫检查点抑制剂治疗：如何选择？
Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12.
2
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.携驱动基因突变的肺癌的免疫检查点阻断：择路需明智。
Am Soc Clin Oncol Educ Book. 2020 May;40:372-384. doi: 10.1200/EDBK_280795.
3
Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?转移性非小细胞肺癌的免疫疗法：真的是显而易见的选择吗？
Cancer. 2024 Aug 1;130(15):2577-2581. doi: 10.1002/cncr.35350. Epub 2024 May 6.
4
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.基于药物的评分在接受一线免疫治疗的晚期非小细胞肺癌患者中的预测能力。
Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
5
[Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].伊匹木单抗-纳武单抗作为转移性非小细胞肺癌的一线治疗方案
Bull Cancer. 2021 Mar;108(3):231-233. doi: 10.1016/j.bulcan.2021.01.005. Epub 2021 Feb 20.
6
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌：合理选择。
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
7
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
8
Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.免疫检查点抑制剂治疗非小细胞肺癌的预测性遗传生物标志物。
Immunotherapy. 2022 Mar;14(4):249-257. doi: 10.2217/imt-2021-0175. Epub 2022 Jan 25.
9
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
10
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.免疫检查点抑制剂与二线化疗治疗一线化疗耐药的肺癌患者。
Respir Med Res. 2020 Nov;78:100788. doi: 10.1016/j.resmer.2020.100788. Epub 2020 Aug 28.

引用本文的文献

1
Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).建立一种超快速下一代测序方法作为非鳞状非小细胞肺癌诊断时的补充检测；单中心（法国尼斯市LPCE）的经验
Cancers (Basel). 2022 Apr 30;14(9):2258. doi: 10.3390/cancers14092258.